Literature DB >> 3259890

Cyclosporin A and anti-glomerular basement membrane antibody glomerulonephritis in rats.

A Wood1, D Adu, R J Birtwistle, D B Brewer, J Michael.   

Abstract

In a telescoped model of antiglomerular basement membrane (GBM) antibody induced nephritis, Lewis strain rats were injected in the footpad with rabbit IgG on day 0 and then given a single intravenous injection of rabbit anti-rat GBM antibody on day 5. Proteinuria developed within 24 h and renal histology 7 days later showed a focal or diffuse proliferative glomerulonephritis. In this study rats treated as above were given Cyclosporin A (CyA) 20 mg/kg daily by intraperitoneal injection from day 0 or from day 5. Rats given CyA plus anti-GBM antibody developed extensive glomerular infiltration with polymorphs and glomerular thrombosis, lesions not seen with unmodified anti-GBM nephritis or in rats who received CyA alone. The mechanism by which CyA given prior to or at the onset of immunological insult in this model worsens glomerular injury is unclear.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259890      PMCID: PMC2013209     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  11 in total

1.  THE PATHOGENIC ROLE OF THE COAGULATION PROCESS IN RABBIT MASUGI NEPHRITIS.

Authors:  P VASSALLI; R T MCCLUSKEY
Journal:  Am J Pathol       Date:  1964-10       Impact factor: 4.307

2.  Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient.

Authors:  R S Bonser; D Adu; I Franklin; P McMaster
Journal:  Lancet       Date:  1984-12-08       Impact factor: 79.321

3.  DNA-anti-DNA circulating complexes in the nephritis of systemic lupus erythematosus.

Authors:  D Adu; J Dobson; D G Williams
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

4.  The role of polymorphonuclear leucocytes in the autologous phase of nephrotoxic nephritis.

Authors:  P F Naish; N M Thomson; I J Simpson; D K Peters
Journal:  Clin Exp Immunol       Date:  1975-10       Impact factor: 4.330

5.  Glomerular thrombosis and cortical infarction in cyclosporin-treated rabbits with acute serum sickness.

Authors:  G H Neild; K Ivory; D G Williams
Journal:  Br J Exp Pathol       Date:  1984-02

6.  Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice.

Authors:  D Israel-Biet; L H Noel; M A Bach; M Dardenne; J F Bach
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

7.  T lymphocyte participation in antibody-induced experimental glomerulonephritis.

Authors:  P G Tipping; T J Neale; S R Holdsworth
Journal:  Kidney Int       Date:  1985-03       Impact factor: 10.612

8.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

9.  Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury.

Authors:  H Shulman; G Striker; H J Deeg; M Kennedy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

10.  Evidence for a pathogenic role of a cell-mediated immune mechanism in experimental glomerulonephritis.

Authors:  A K Bhan; E E Schneeberger; A B Collins; R T McCluskey
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  3 in total

1.  Cyclosporin A in the prevention and treatment of experimental autoimmune glomerulonephritis in the brown Norway rat.

Authors:  J Reynolds; S J Cashman; D J Evans; C D Pusey
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

2.  Prostaglandin E1 suppresses macrophage infiltration and ameliorates injury in an experimental model of macrophage-dependent glomerulonephritis.

Authors:  V Cattell; J Smith; H T Cook
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.